Samsung Biologics acquires Rockville facility, expanding U.S. presence, boosting capacity, retaining workforce, and strengthening global biologics manufacturing partnerships and innovation.
Samsung Biologics has successfully finalized the acquisition of a large-scale biologics manufacturing facility located in Rockville, representing a strategic milestone in the company’s global expansion efforts. This move marks the company’s first operational footprint in the United States and reflects its long-term commitment to strengthening manufacturing capabilities and innovation within one of the world’s most advanced pharmaceutical markets.
The newly integrated facility significantly enhances Samsung Biologics’ production infrastructure. It includes two manufacturing plants with a combined drug substance capacity of 60,000 liters, capable of supporting both clinical-stage development and large-scale commercial production. Following this acquisition, the company’s total global manufacturing capacity has risen to approximately 845,000 liters, reinforcing its position as one of the leading contract development and manufacturing organizations (CDMOs) worldwide. The deal, valued at $353 million, underscores Samsung Biologics’ intent to expand its global supply network while building a stronger presence in North America.
Situated within a prominent biotechnology cluster, the Rockville facility is expected to play a vital role in strengthening regional and global biopharmaceutical production. Importantly, the company has retained over 500 skilled employees at the site, preserving local expertise and contributing to the continued growth of the life sciences workforce in Maryland. This integration allows Samsung Biologics to better serve its diverse client base, which includes more than 145 pharmaceutical and biotechnology companies globally, as well as 17 of the top 20 pharmaceutical firms such as AstraZeneca, Eli Lilly, and Pfizer.
Through its extensive partnerships, Samsung Biologics contributes to the development and manufacturing of treatments targeting critical health conditions, including cancer, COVID-19, autoimmune diseases, and inflammatory disorders. The addition of the Rockville site is expected to further strengthen these collaborations by increasing production flexibility and accelerating delivery timelines for essential therapies.
To commemorate the acquisition, Samsung Biologics hosted an official opening and ribbon-cutting ceremony on March 31. The event was attended by key public officials, including Wes Moore and Susan Lee, highlighting the importance of this investment for the region’s economic and scientific landscape. The facility is strategically located along the I-270 Technology Corridor, an area known for its strong ecosystem of federal laboratories, academic institutions, and biotech companies that collaborate to drive innovation.
Company leadership emphasized that this expansion strengthens Samsung Biologics’ ability to deliver life-saving medicines globally while deepening its engagement in the U.S. market. The experienced workforce at Rockville is expected to play a key role in maintaining high operational standards and supporting the company’s broader manufacturing network.
Looking forward, Samsung Biologics plans to continue fulfilling existing manufacturing commitments, including product supply agreements with GSK. At the same time, the company intends to invest further in the facility by upgrading technologies and expanding production capacity. These future enhancements will enable the site to meet growing demand and support the next generation of biologic therapies, reinforcing Samsung Biologics’ position as a global leader in biopharmaceutical manufacturing.
